Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Oppenheimer從事臨床生物製藥的Gossamer Bio Inc（納斯達克：GOSS）進行覆蓋，給予Outperform評級和9美元的目標股價。
Gossamer Bio is focused on developing and commercializing seralutinib for pulmonary arterial hypertension. It stands out with its clean long-term safety profile, Oppenheimer said.
Gossamer Bio專注於開發和商業化seralutinib以用於肺動脈高壓。它由於長期良好的安全性而脫穎而出，Oppenheimer表示。
Competitors like Merck & Co Inc's (NYSE:MRK) Winrevair require frequent monitoring for hemoglobin increases, thrombocytopenia, and gastrointestinal bleeding. It may require dose reductions or drug holidays.
像Merck＆Co Inc（紐交所：MRK）的Winrevair這樣的競爭對手需要經常監測血紅蛋白增加，血小板減少和胃腸道出血。它可能需要劑量減少或藥物休假。
In May, Gossamer Bio and Italy-based Chiesi Farmaceutici S.p.A entered a global collaboration and license agreement to develop and commercialize seralutinib.
五月份，Gossamer Bio和意大利的Chiesi Farmaceutici S.p.A簽署了全球合作和許可協議，以開發和商業化seralutinib。
Following the readout of the Phase 2 TORREY Study in patients with PAH, Gossamer initiated the Phase 3 PROSERA Study in 2023.
在對PAH患者進行第2期TORREY研究的讀數後，Gossamer啓動了2023年的第3期PROSERA研究。
Gossamer and Chiesi plan to initiate a global Phase 3 registrational study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) in mid-2025 and to evaluate seralutinib in additional indications.
Gossamer和Chiesi計劃在2025年中期啓動全球第3期可註冊的肺動脈高壓相關間質性肺病（PH-ILD）研究，並在其他適應症中評估seralutinib。
Oppenheimer says including Japanese trial sites could help seralutinib gain approval in Japan, the world's second-largest PAH market, and attract potential partnerships. Additionally, delays for WInrevair in Europe underscore the importance of opportunities outside the U.S.
Oppenheimer表示，包括日本試驗場地可以幫助seralutinib獲得日本批准，這是世界第二大PAH市場，並吸引潛在的合作伙伴。此外，Winrevair在歐洲的延遲凸顯了美國以外的機遇的重要性。
Seralutinib's safety and efficacy profile are "a preferred choice among severe PAH patients who are not adequately served by currently available therapies (~65% take 2-3 drugs)," analysts noted.
分析師指出，Seralutinib的安全性和有效性已成爲“不受當前可用療法充分服務（約65％服用2-3種藥物）的嚴重PAH患者的首選”。
The analyst adds that Gossamer has strategically positioned seralutinib to enter large, underserved markets such as Japan. "We see shares trading below cash as creating an attractive entry point at current levels."
該分析師補充說，Gossamer已將seralutinib策略地定位爲進入日本等大型未開發市場，“我們認爲股價低於現金，爲當前水平提供了有吸引力的入場點。”
With pro forma cash of $396 million providing sufficient runway into the second quarter of 2026 and shares currently trading below cash, this can be seen as an attractive entry for long-term investors.
由於Gossamer的Pro forma現金爲3.96億美元，足以提供到2026年第二季度的足夠時間，並且股票目前低於現金，這可以視爲長期投資者的有吸引力的入口。
Price Action: GOSS shares are up 21.1% at $1.00 at last check Tuesday.
價格行動：截至上週二最後一個檢查，GOSS股價上漲21.1％，爲1.00美元。
Now Read: Chipmakers, Cruise Lines, Crypto Rally, Nvidia Reclaims $3 Trillion; Blue Chips, Small Caps Dip: What's Driving Markets Tuesday?
現在閱讀：芯片製造商，郵輪概念，加密貨幣上漲，英偉達回收3萬億美元；藍籌股，小盤股下跌：週二是什麼推動市場？